N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity

M. Taccone-Gallucci, S. Manca-di-Villahermosa, L. Battistini, R. G. Stuffler, M. Tedesco, M. Maccarrone

Research output: Contribution to journalArticlepeer-review


Reactive oxygen species formation and release of proinflammatory/pro-atherogenic cytokines, that is, interleukin 1-β and tumor necrosis factor-α, need the activation of the arachidonic acid cascade via the enzyme 5-lipoxygenase (5-Lox). 5-Lox activity and expression are significantly increased in peripheral blood mononuclear cells (PBMCs) of end-stage renal disease (ESRD) patients on maintenance hemodialysis (HD). Diets enriched with n-3 polyunsaturated fatty acids (PUFAs) (ω-3) have been associated to a lower incidence of coronary heart disease (CHD) and a reduction in atherosclerotic lesions. Ω-3 may interfere with the arachidonic acid cascade by inhibiting 5-Lox. Lipid peroxidation, leukotriene B4 (LTB4) production, 5-Lox activity and expression were investigated in PBMC isolated from ESRD patients under maintenance HD before and after a 3-month oral supplementation with ω-3 at a daily dose of 2700 mg of n-3 PUFAs at the average eicosapentaenoic acid/docosaesaenoic acid ratio of 1.2 and finally after a further 3-month washout with no ω-3 supplementation. PBMCs from non-uremic volunteers were also investigated for comparison to normal parameters. Administration of ω-3 reduced significantly lipid peroxidation (P4 synthesis (P

Original languageEnglish
Pages (from-to)1450-1454
Number of pages5
JournalKidney International
Issue number8
Publication statusPublished - Apr 2006


  • 5-lipoxygenase
  • Apoptosis
  • Atherosclerosis
  • Hemodialysis
  • N-3 PUFAS
  • Oxidative stress

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity'. Together they form a unique fingerprint.

Cite this